Ipsen to start second resupply of Increlex in the US in September
In collaboration with the US Food and Drug Administration (FDA), Ipsen is releasing a second batch of Increlex in 2014. The first batch was made available for distribution
The US Food and Drug Administration (FDA) has approved Pfizer’s Tukysa (tucatinib) along with pertuzumab and trastuzumab as a maintenance therapy for breast cancer.
Aripiprazole lauroxil is an investigational, new, once-monthly, long-acting injectable atypical antipsychotic. The NDA is based on the positive results from the randomized, multicenter, double-blind, placebo-controlled, phase III trial